Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia

ClinicalTrials.gov ID: NCT03593213

Public ClinicalTrials.gov record NCT03593213. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 13, 2026, 3:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

1. To evaluate the efficacy and safety of cariprazine at a target dose of 4.5 milligram per day (mg/d) compared with placebo in prevention of relapse in patients with schizophrenia 2. To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/d compared with placebo in prevention of relapse in patients with schizophrenia who were initially stabilized on a target dose of 4.5 mg/d

Study identification

NCT ID
NCT03593213
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
AbbVie
Industry
Enrollment
587 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 64 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 29, 2018
Primary completion
Feb 10, 2021
Completion
Feb 10, 2021
Last update posted
Apr 10, 2022

2018 – 2021

United States locations

U.S. sites
42
U.S. states
14
U.S. cities
38
Facility City State ZIP Site status
Pillar Clinical Research Bentonville Arkansas 72712
Woodland International Research Group Little Rock Arkansas 72211
Woodland Research Northwest, LLC Rogers Arkansas 72758
Advanced Research Center, Inc. Anaheim California 92805
CITrials - Bellflower Bellflower California 90706
Synexus Clinical Research US, Inc. Cerritos California 90703
ATP Clinical Research, Inc. Costa Mesa California 92626
California Pharmaceutical Research Institute, Inc. Costa Mesa California 92626
ProScience Research Group Culver City California 90230
Collaborative Neuroscience Research Network, LLC. Garden Grove California 92845
Behavioral Research Specialists, LLC Glendale California 91206
Omega Clinical Trials La Habra California 90631
Synergy San Diego Lemon Grove California 91945
Alliance Research Long Beach California 90807
Excell Research, Inc Oceanside California 92056
Orange County Neuropsychiatric Research Center, LLC Orange California 92868
CNRI-Los Angeles Pico Rivera California 90660
University of California San Diego San Diego California 92103-8229
Schuster Medical Research Institute Sherman Oaks California 91423
Collaborative Neuroscience Research, LLC Torrance California 90502
Wilks & Safirstein MD PA D/B/A MD Clinical Hallandale Florida 33009
Southern Winds Hospital Hialeah Florida 33012
Research Centers of America Hollywood Florida 33024
Synexus Clinical Research, Inc Atlanta Georgia 30328
Atlanta Center for Medical Research Atlanta Georgia 30331
iResearch Atlanta LLC Decatur Georgia 30030
Atlanta Behavioral Research, LLC Dunwoody Georgia 30338
AMITA Health Alexian Brothers Center for Psychiatric Research Hoffman Estates Illinois 60169
Louisiana Clinical Research Shreveport Louisiana 71101
CBH Health LLC Gaithersburg Maryland 20877
Altea Research Las Vegas Nevada 85012
Alea Research Institute Las Vegas Nevada 89102
Hassman Research Institute Berlin New Jersey 08009
Neurobehavioral Research, Inc. Cedarhurst New York 11516
New Hope Clinical Research Charlotte North Carolina 28211
Clinical Inquest Center Ltd. Beavercreek Ohio 45431
OSY Psychiatry Department Columbus Ohio 43210
Professional Psychiatric Services Mason Ohio 45069
Sooner Clinical Research Oklahoma City Oklahoma 23112
Community Clinical Research, Inc. Austin Texas 78754
Pillar Clinical Research Richardson Texas 75042
Pillar Healthcare Richardson Texas 75080

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 55 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03593213, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 10, 2022 · Synced Sep 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03593213 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →